| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 02/01/2011 | US7879353 comprising copolyester comprising reaction product of a polycondensation polyester and glycolide, and drug such as indomethacin, diclofenac sodium, and ketoprofen; pharmacokinetics |
| 02/01/2011 | US7879352 Scored pharmaceutical tablets comprising a plurality of segments |
| 02/01/2011 | US7879351 liposomal aminoglycoside formulation comprising liposome having lipid bilayer encapsulating an aminoglycoside where the lipid bilayer comprises neutral phospholipid and sterol; anionic lipids-free; respiratory system disorders; cystic fibrosis; tissue-targeted therapy |
| 02/01/2011 | US7879346 Cosmetic compositions for improving the performance of transfer-resistant and long-wearing |
| 02/01/2011 | US7879344 contains antiitch agent; for use in wipes and absorbent articles, and transdermal patches |
| 02/01/2011 | US7879343 Burn treatment method and composition |
| 02/01/2011 | US7879333 Methods for preparing and delivering adjuvant compositions |
| 02/01/2011 | US7879323 Antibodies to fibroblast growth factor-like polypeptides |
| 02/01/2011 | US7879320 Sustained release interferon dosage form for use in treatment of multiple sclerosis |
| 02/01/2011 | US7879317 biocompatible amphiphilic copolymer of hydrophilic and hydrophobic blocks, and a polylactic acid derivative having a terminal carboxy metal salt; hydrophilic outer shell and hydrophobic inner core physically trap hydrophobic drug; prolonged retention time in the bloodstream on delivery |
| 02/01/2011 | US7879313 Nanoparticles for protein drug delivery |
| 02/01/2011 | US7879312 Nanoparticles for protein drug delivery |
| 02/01/2011 | US7879304 Creating monodisperse droplets of a precursor aqueous or alcohol based solution comprising tetraethylorthosilicate with an amphiphile to form a sol using a vibrating orifice aerosol generator; evaporating solvent; heating to promote condensation of tetraethylorthosilicate to produce non-hollow mesoporous |
| 02/01/2011 | US7879028 Osmotic delivery systems and piston assemblies for use therein |
| 02/01/2011 | US7879027 Controlled release devices for fusion of osteal structures |
| 02/01/2011 | US7879026 Controlled adjustment of medicine dispensation from an infusion pump device |
| 02/01/2011 | US7879025 Fluid delivery system and flow control therefor |
| 02/01/2011 | US7879019 Method of opening reservoir of containment device |
| 02/01/2011 | US7878193 Capsule for taking an active substance which can be inhaled |
| 02/01/2011 | CA2695611C Active targeting polymer micelle encapsulating drug, and pharmaceutical composition |
| 02/01/2011 | CA2688915C Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
| 02/01/2011 | CA2543324C Rapidly disintegrating films for delivery of pharmaceutical or cosmetic agents |
| 02/01/2011 | CA2536728C Method and composition for treating rhinitis |
| 02/01/2011 | CA2505918C A liposome having bound albumin and peg |
| 02/01/2011 | CA2488220C Medicament with delayed active constituent release containing 1-dimethylamino-3-(3-methoxyphenyl)-2-methylpentan-3-ol |
| 02/01/2011 | CA2483110C Use of a mare milk concentrate dried on a biologically inert, highly disperse matrix |
| 02/01/2011 | CA2483002C New pharmaceutical composition |
| 02/01/2011 | CA2482972C The use of hydroxypyridone-derivatives in wound healing |
| 02/01/2011 | CA2481468C Medicaments containing betamimetic drugs and a novel anticholinesterase drug |
| 02/01/2011 | CA2477881C Formoterol superfine formulation |
| 02/01/2011 | CA2476298C Carbocyclic and oxacarbocyclic fumaric acid oligomers |
| 02/01/2011 | CA2470971C Use of pharmaceutical composition containing epidermal growth factor (egf) for preventing diabetic limb amputation |
| 02/01/2011 | CA2466657C Soluble drug extended release system |
| 02/01/2011 | CA2464689C Modified release tamsulosin tablets |
| 02/01/2011 | CA2461457C Multi-core press-coated molded product, and method and apparatus for manufacturing the same |
| 02/01/2011 | CA2454804C Probiotic lactobacillus salivarius strains |
| 02/01/2011 | CA2453442C Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases |
| 02/01/2011 | CA2446994C Prostanoic acid derivatives as agents for lowering intraocular pressure |
| 02/01/2011 | CA2427375C Pharmaceutical dronedarone composition for parenteral administration |
| 02/01/2011 | CA2425172C Methods of decreasing or preventing pain using spicamycin derivatives |
| 02/01/2011 | CA2408685C Liquid pharmaceutical composition containing an erythropoietin derivate |
| 02/01/2011 | CA2405508C Hydrophilic/lipophilic polymeric matrix dosage formulation |
| 02/01/2011 | CA2404368C Pharmaceutical compositions |
| 02/01/2011 | CA2402589C Compositions and methods for trapping and inactivating pathogenic microbes and spermatozoa |
| 02/01/2011 | CA2393298C Compositions and methods for stabilizing biological molecules upon lyophilization |
| 02/01/2011 | CA2364342C Agglomerates by crystallisation |
| 02/01/2011 | CA2353959C A medicinal aerosol formulation |
| 02/01/2011 | CA2342133C Ophthalmic formulations |
| 02/01/2011 | CA1341610C Osteogenic polypeptides |
| 01/27/2011 | WO2011011733A2 Factor replacement therapy |
| 01/27/2011 | WO2011011541A1 Ferric citrate dosage forms |
| 01/27/2011 | WO2011011351A2 A stable pharmaceutical omeprazole formulation for oral administration |
| 01/27/2011 | WO2011011333A2 Nanomolding micron and nano scale features |
| 01/27/2011 | WO2011011318A1 Process for the continuous manufacture of a polyisobutylene based transdermal patch |
| 01/27/2011 | WO2011011300A2 Differentiation of human embryonic stem cells |
| 01/27/2011 | WO2011011252A1 Methods of attenuating the loss of functional status |
| 01/27/2011 | WO2011011099A1 Multi-layered gradient vaginal ring |
| 01/27/2011 | WO2011010732A1 Composition for external preparation for skin |
| 01/27/2011 | WO2011010645A1 Fentanyl-containing adhesive preparation for external use |
| 01/27/2011 | WO2011010605A1 Microneedle array |
| 01/27/2011 | WO2011010556A1 Transdermal preparation |
| 01/27/2011 | WO2011010399A1 Corneal endothelial cell proliferation promoter |
| 01/27/2011 | WO2011010324A1 Oral pharmaceutical composition of rasagiline and process for preparing thereof |
| 01/27/2011 | WO2011010316A1 Pharmaceutical compositions of irbesartan |
| 01/27/2011 | WO2011010190A1 Antibacterial composition comprising fluoroquinlone such as norfloxacin together with tripmethoprim |
| 01/27/2011 | WO2011010156A1 Fas (apo-1, cd95) targeted platforms for intracellular drug delivery |
| 01/27/2011 | WO2011010132A1 Sustained-release composition comprising compound 600 |
| 01/27/2011 | WO2011010131A1 Compositions comprising an oxoisoquinoline methylbenzamide and a polymer |
| 01/27/2011 | WO2011009956A1 Injectable aqueous solution containing artesunate |
| 01/27/2011 | WO2011009906A1 Preparation and delivery of food additives |
| 01/27/2011 | WO2011009862A1 Nigella extracts for the treatment of symptoms connected to impaired or imbalanced neurotransmission |
| 01/27/2011 | WO2011009852A2 Pharmaceutical compositions |
| 01/27/2011 | WO2011009818A1 Beta 2 adrenergic receptor agonists such as terbutaline for use in the treatment of nocturnal hypoglycemia |
| 01/27/2011 | WO2011009604A1 Oxidation-stabilized tamper-resistant dosage form |
| 01/27/2011 | WO2011009603A1 Tamper-resistant dosage form for oxidation-sensitive oploids |
| 01/27/2011 | WO2011009602A1 Hot-melt extruded controlled release dosage form |
| 01/27/2011 | WO2011009360A1 Pharmaceutical composition for treatment of type 2 diabetes in mammals including human beings |
| 01/27/2011 | WO2010138661A8 Nanoparticulate anticancer compositions and methods for making the same |
| 01/27/2011 | WO2010135534A3 Compositions for the treatment of metastatic cancer and methods of use thereof |
| 01/27/2011 | WO2010130462A3 Phosphate-free pharmaceutical composition for the treatment of glaucoma |
| 01/27/2011 | WO2010119455A3 An injectable sustained release pharmaceutical composition |
| 01/27/2011 | WO2010117753A3 Peptide compositions for oral care systems |
| 01/27/2011 | WO2010090876A3 Satiation peptide administration |
| 01/27/2011 | WO2010065456A3 Flowable pharmaceutical depot |
| 01/27/2011 | WO2010045512A3 Processes and compositions for liposomal and efficient delivery of gene silencing therapeutics |
| 01/27/2011 | WO2010041722A3 Pharmaceutical composition comprising a prostaglandin |
| 01/27/2011 | WO2010009065A3 Amphipathic peptide compositions |
| 01/27/2011 | WO2009156180A3 Polymeric delivery systems for active agents |
| 01/27/2011 | WO2009135855A3 Encapsulation of biologically active agents |
| 01/27/2011 | US20110021974 Retinitis pigmentosa treatment and prophalaxis |
| 01/27/2011 | US20110021972 Composition and Device Structure For Iontophoresis |
| 01/27/2011 | US20110021970 Non-invasive energy upconversion methods and systems for in-situ photobiomodulation |
| 01/27/2011 | US20110021642 Water-soluble acrylic acid salt polymer and gelling base |
| 01/27/2011 | US20110021631 Method of preparing stabilized pharmaceutical compositions comprising active ingredients susceptible to conversion to alternate polymorph forms |
| 01/27/2011 | US20110021628 CRYSTALLINE FORM OF y-AMINOBUTYRIC ACID ANALOG |
| 01/27/2011 | US20110021452 Lyophilized preparation of stabilized anthracycline compounds |
| 01/27/2011 | US20110021355 Formulation with reduced hygroscopicity |
| 01/27/2011 | US20110020458 Sustained-release composition of drugs encapsulated in microparticles of hyaluronic acid |
| 01/27/2011 | US20110020457 Polymer-surfactant nanoparticles for sustained release of compounds |
| 01/27/2011 | US20110020456 Lanthanum composition |